$21.1M capital deployed

30% primary ownership

Jun '11 initial capital deployed

return to top

Why NovaSom?

Headquartered in Glen Burnie, MD, NovaSom is a leader in Obstructive Sleep Apnea (“OSA”) home testing, with the AccuSom® home sleep test, the only comprehensively supported home sleep test that provides continuous patient support and next-day test results and interpretation for health care professionals.

The FDA-cleared AccuSom is as accurate as sleep lab testing, and significantly more convenient and comfortable for patients. Patients are able to test around their own schedule and can sleep in their own bed, which helps eliminate “first night” effect and improves data collection. AccuSom is currently covered for more than 150 million commercially insured U.S. lives.

NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider, is classified by CMS as an Independent Diagnostic Testing Facility and is an Approved Out of Center Sleep Testing Supplier by the American Academy of Sleep Medicine.

The OSA diagnostic market in the U.S. is estimated to be approximately $4 billion and is growing 15-20% annually. Only 3 million sufferers in the U.S. have been diagnosed to date, out of an estimated 40 million moderate to severe OSA sufferers.

During the third quarter of 2014, AccuSom was featured in a New York Times article entitled, “A Sleep Apnea Test Without a Night in the Hospital.” In the article, reporter Donald G. McNeil Jr. highlighted AccuSom’s ease of use and accurate data over a three-night period, and explained how technology has drastically improved during the 10 years since he was first diagnosed with sleep apnea.

By giving patients the option to conduct tests for OSA in their homes, we hope to identify and treat more of the millions of undiagnosed sufferers. Safeguard’s financial and operational support have augmented our traction to date, expanded our market penetration and ultimately impacted our patients’ quality of life.

– John Spitznagel, CEO, NovaSom